A Pilot Study of Individualized Maximum Repeatable Dose (iMRD), a New Dose Finding System, of Weekly Gemcitabine for Patients With Metastatic Pancreas Cancer

• TAKAHASHI Yutaka

  Department of Surgical Oncology, Cancer Research Institute, Kanazawa University

• MAI Masayoshi

  Department of Surgical Oncology, Cancer Research Institute, Kanazawa University

• SAWABU Norio

  Department of Internal Medicine/Medical Oncology, Cancer Research Institute, Kanazawa University

• NISHIOKA Kenji

  Nishioka Consulting

収録刊行物

• Pancreas

  Pancreas 30 (3), 206-210, 2005-04-01

キーワード

• tailored-dose chemotherapy
• gemcitabine
• time to progressive disease
• pancreas cancer

詳細情報

• CRID: 1571698600192773760
• NII論文ID: 10016140022
• NII書誌ID: AA10674276
• ISSN: 08853177
• 本文言語コード: en
• データソース種別:
  • CiNii Articles